263 related articles for article (PubMed ID: 19271568)
21. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
[TBL] [Abstract][Full Text] [Related]
22. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
23. Mast cells and mastocytosis.
Söderholm JD
Dig Dis; 2009; 27 Suppl 1():129-36. PubMed ID: 20203509
[TBL] [Abstract][Full Text] [Related]
24. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
Hahn HP; Hornick JL
Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome.
Sonneck K; Florian S; Müllauer L; Wimazal F; Födinger M; Sperr WR; Valent P
Int Arch Allergy Immunol; 2007; 142(2):158-64. PubMed ID: 17057414
[TBL] [Abstract][Full Text] [Related]
26. [Systemic mastocytosis--new therapeutic strategies].
Maniu CM; Ribi C; Spertini F
Rev Med Suisse; 2013 Jan; 9(368):17-21. PubMed ID: 23367698
[TBL] [Abstract][Full Text] [Related]
27. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).
Pardanani A
Blood; 2013 Apr; 121(16):3085-94. PubMed ID: 23426950
[TBL] [Abstract][Full Text] [Related]
28. Novel approaches in the treatment of systemic mastocytosis.
Quintas-Cardama A; Aribi A; Cortes J; Giles FJ; Kantarjian H; Verstovsek S
Cancer; 2006 Oct; 107(7):1429-39. PubMed ID: 16948123
[TBL] [Abstract][Full Text] [Related]
29. Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine.
Lock AD; McNamara CJ; Rustin MH
Clin Exp Dermatol; 2015 Mar; 40(2):142-5. PubMed ID: 25515765
[TBL] [Abstract][Full Text] [Related]
30. Systemic Mastocytosis: Clinical Update and Future Directions.
Tremblay D; Carreau N; Kremyanskaya M; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):728-38. PubMed ID: 26382091
[TBL] [Abstract][Full Text] [Related]
31. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Pardanani A; Reichard K; Tefferi A
Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
[TBL] [Abstract][Full Text] [Related]
32. Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.
Zuluaga Toro T; Hsieh FH; Bodo J; Dong HY; Hsi ED
Br J Haematol; 2007 Oct; 139(1):31-40. PubMed ID: 17662084
[TBL] [Abstract][Full Text] [Related]
33. Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis?
Falleti J; Borgia L; Lalinga AV; De Cecio R; Natella V; Patitucci G; Vita G
Pathol Res Pract; 2012 Nov; 208(11):683-6. PubMed ID: 22963840
[TBL] [Abstract][Full Text] [Related]
34. [Systemic mastocytosis. Classification, symptoms, therapy].
Kraemer DM; Grunewald SM; Kolb-Mäurer A
Med Klin (Munich); 2004 Mar; 99(3):131-6. PubMed ID: 15024485
[TBL] [Abstract][Full Text] [Related]
35. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
[TBL] [Abstract][Full Text] [Related]
36. Mastocytosis: classification, diagnosis, and clinical presentation.
Castells MC
Allergy Asthma Proc; 2004; 25(1):33-6. PubMed ID: 15055560
[TBL] [Abstract][Full Text] [Related]
37. Adult mastocytosis: a review of the Santo António Hospital 's experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease.
Fernandes IC; Teixeira Mdos A; Freitas I; Selores M; Alves R; Lima M
An Bras Dermatol; 2014; 89(1):59-66. PubMed ID: 24626649
[TBL] [Abstract][Full Text] [Related]
38. Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.
Lange M; Hartmann K; Carter MC; Siebenhaar F; Alvarez-Twose I; Torrado I; Brockow K; Renke J; Irga-Jaworska N; Plata-Nazar K; Ługowska-Umer H; Czarny J; Belloni Fortina A; Caroppo F; Nowicki RJ; Nedoszytko B; Niedoszytko M; Valent P
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806685
[TBL] [Abstract][Full Text] [Related]
39. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
40. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone.
Pullarkat V; Bedell V; Kim Y; Bhatia R; Nakamura R; Forman S; Sun J; Senitzer D; Slovak ML
Leuk Res; 2007 Feb; 31(2):261-5. PubMed ID: 16876862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
